Trial Profile
Observational study of Miglustat/Zavesca for safety and efficacy in patients with type 1 Gaucher disease. An open, multicenter, non-interventional, prospective Phase IV study.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 04 Apr 2014
Price :
$35
*
At a glance
- Drugs Miglustat (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Acronyms MIGADO
- Sponsors Actelion Pharmaceuticals
- 04 Apr 2014 New trial record